Mike Mangone, Ph.D.

Mike has spent more than 15 years in strategic, operational and drug development roles in the biotech and life science space. Most recently, he was Vice President of Business Development and Operations at BridgeBio (BBIO) where he advanced two late-stage portfolio companies, Phoenix Tissue Repair and Origin Biosciences. At Origin, Mike managed operations through clinical development; oversaw FDA and EMA approvals; and directed corporate strategy for the launch of Nulibry, BridgeBio’s first commercial asset. Prior, Mike consulted for a wide range of biotech, pharma and private equity clients on projects spanning corporate, portfolio and commercial strategy, and business development in the oncology, inflammation and immunology, and autoimmunity disease spaces among other areas. Mike also spent time at Flagship Pioneering helping create early-stage platform companies centered on breakthrough science, such as Ring Therapeutics.

Mike is a scientist by training and developed small molecule inhibitors targeting key oncogenic and inflammatory pathways at the Center for Lymphoid Malignancy at Columbia University. He received his Ph.D. in Pathobiology working on cancer vaccine development at NYU School of Medicine and earned an A.B. in molecular biology from Princeton University.

Roland Meier, M.D., Ph.D

Roland has over 20 years of experience in clinical practice, research, and industry in all phases of drug development. He has served in immuno-oncology leadership roles at Bristol Myers Squibb, Eli Lilly, and most recently at Kyowa Kirin. Earlier in his career, Roland worked in Medical Affairs, Drug Safety, and Clinical Development. Roland has worked on multiple therapeutics from Phase 1 to Phase 4. He has contributed to commercially available drugs including Jevtana, Kadcyla, Herceptin, Avastin, Venclexta, Empliciti, and Poteligeo. His immuno-oncology contributions includes checkpoint inhibitors Opdivo and Yervoy and various immune-stimulatory T-cell agonists including urelumab (4-1BB and GITR); and other immuno-modulatory agents including IDO inhibitors and RNA vaccines.

During his postdoctoral fellowship at the Lawrence Berkeley National Laboratory, Roland investigated the role of the tumor microenvironment on tumor initiation and progression and characterized a protein that could mediate resistance to targeted therapy in breast cancer.

After Roland graduated with an MD from the University of Zurich, Switzerland, he worked as a resident at the Children’s Hospital of Zurich and subsequently at the University Hospital in Lausanne, Switzerland where he pursued his passion for research and was awarded an M.D., Ph.D.